Overrepresentation of the SpSp Genotype in AML-M3 and -M4 Subtypes
. | APL-M3 . | M4 . | M2 . | M0156 Low Expressors . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
. | Case No. . | Sex . | Karyotype . | Case No. . | Sex . | Karyotype . | Case No. . | Sex . | Karyotype . | Case No. . | Sex . | Karyotype . |
SpSp | 801 | Male | N/D | 921 | Male | N/D | 1010 | Male | N/D | 3001 (M0) | Female | Normal |
803 | Male | t15; 17 | 933 | Male | Abnormal 7, 13, 14 | 1015 | Female | Normal | 3005 (M6) | Male | N/D | |
812 | Male | N/D | 935 | Female | N/D | 1020 | Female | N/D | 3010 (M5) | Male | Normal | |
823 | Male | t15; 17 | 940 | Male | Normal | 1027 | Male | inv 16 | 3020 (M1) | Male | Tetraploid | |
1637 | Male | t15; 17 | 947 | Male | Normal | 3030 (M1) | Female | N/D | ||||
1787 | Female | t15; 17 | 960 | Male | N/D | |||||||
1941 | Male | t15; 17 | 966 | Female | N/D | |||||||
2008 | Male | t15; 17 | 972 | Male | N/D | |||||||
2098 | Female | t15; 17 | 980 | Male | N/D | |||||||
2262 | Male | t15; 17 | ||||||||||
2312 | Female | t15; 17 | ||||||||||
2343 | Female | t15; 17 | ||||||||||
2354 | Male | t15; 17 | ||||||||||
2379 | Female | t15; 17 | ||||||||||
2429 | Male | t15; 17 | ||||||||||
SpN | 2399 | Male | N/D | 927 | Male | Deletion 10.16 | 1030 | Female | N/D | 3034 (M1) | Male | Normal |
840 | Male | t15; 17 | 955 | Male | Trisomy 21 | 3038 (M5) | Male | Normal | ||||
3045 (M5) | Male | N/D | ||||||||||
NN | 2394 | Male | t15; 17 | 1035 | Male | N/D | ||||||
1848 | Female | t15; 17 | 1038 | Male | t8; 21 | |||||||
1040 | Female | 46xx,i(14q) |
. | APL-M3 . | M4 . | M2 . | M0156 Low Expressors . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
. | Case No. . | Sex . | Karyotype . | Case No. . | Sex . | Karyotype . | Case No. . | Sex . | Karyotype . | Case No. . | Sex . | Karyotype . |
SpSp | 801 | Male | N/D | 921 | Male | N/D | 1010 | Male | N/D | 3001 (M0) | Female | Normal |
803 | Male | t15; 17 | 933 | Male | Abnormal 7, 13, 14 | 1015 | Female | Normal | 3005 (M6) | Male | N/D | |
812 | Male | N/D | 935 | Female | N/D | 1020 | Female | N/D | 3010 (M5) | Male | Normal | |
823 | Male | t15; 17 | 940 | Male | Normal | 1027 | Male | inv 16 | 3020 (M1) | Male | Tetraploid | |
1637 | Male | t15; 17 | 947 | Male | Normal | 3030 (M1) | Female | N/D | ||||
1787 | Female | t15; 17 | 960 | Male | N/D | |||||||
1941 | Male | t15; 17 | 966 | Female | N/D | |||||||
2008 | Male | t15; 17 | 972 | Male | N/D | |||||||
2098 | Female | t15; 17 | 980 | Male | N/D | |||||||
2262 | Male | t15; 17 | ||||||||||
2312 | Female | t15; 17 | ||||||||||
2343 | Female | t15; 17 | ||||||||||
2354 | Male | t15; 17 | ||||||||||
2379 | Female | t15; 17 | ||||||||||
2429 | Male | t15; 17 | ||||||||||
SpN | 2399 | Male | N/D | 927 | Male | Deletion 10.16 | 1030 | Female | N/D | 3034 (M1) | Male | Normal |
840 | Male | t15; 17 | 955 | Male | Trisomy 21 | 3038 (M5) | Male | Normal | ||||
3045 (M5) | Male | N/D | ||||||||||
NN | 2394 | Male | t15; 17 | 1035 | Male | N/D | ||||||
1848 | Female | t15; 17 | 1038 | Male | t8; 21 | |||||||
1040 | Female | 46xx,i(14q) |
Total | Male | Female | Total No. | Male | Female | Total | Male | Female | Total | Male | Female | ||||
SpSp (n) | 15 | 10 | 5 | 9 | 7 | 2 | 4 | 2 | 2 | 5 | 3 | 2 | |||
SpN (n) | 2 | 2 | 0 | 2 | 2 | 0 | 1 | 0 | 1 | 3 | 3 | 0 | |||
NN (n) | 2 | 1 | 1 | 0 | 0 | 0 | 3 | 2 | 1 | 0 | 0 | 0 | |||
19 | 11 | 8 | 8 | ||||||||||||
%SpSp | 79 | 77 | 83 | 82 | 78 | 100 | 44 | 50 | 50 | 62 | 50 | 100 | |||
Highest MPO | High MPO | High MPO | Low MPO | ||||||||||||
Total | Male | Female | Total No. | Male | Female | Total | Male | Female | Total | Male | Female | ||||
SpSp (n) | 15 | 10 | 5 | 9 | 7 | 2 | 4 | 2 | 2 | 5 | 3 | 2 | |||
SpN (n) | 2 | 2 | 0 | 2 | 2 | 0 | 1 | 0 | 1 | 3 | 3 | 0 | |||
NN (n) | 2 | 1 | 1 | 0 | 0 | 0 | 3 | 2 | 1 | 0 | 0 | 0 | |||
19 | 11 | 8 | 8 | ||||||||||||
%SpSp | 79 | 77 | 83 | 82 | 78 | 100 | 44 | 50 | 50 | 62 | 50 | 100 | |||
Highest MPO | High MPO | High MPO | Low MPO | ||||||||||||
APL-M3 cases with identification numbers between 1637 and 2429 were Hispanic.35 MPO genotypes are listed at left as SpSp homozygotes, SpN heterozygotes, or NN homozygotes. The percentage with the SpSp genotype is also shown. Most of the APL-M3 cases were karyotyped as t(15; 17) translocations. In subtypes other than APL, karyotypes listed as normal indicate that no karyotypic abnormality was detected. Approximate relative amounts of MPO gene expression indicated at bottom are from published studies.3,4 27
Abbreviation: ND, not determined.